NIH Clinical Center logo     America's Clinical Research Hospital File folder iconExplore the NIH
Clinical Center
Search the Studies - NIH Clinical Research Studies

Protocol Details

Evaluation, Treatment and Follow up of Patients with lyme Disease

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

02-I-0055

Sponsoring Institute

National Institute of Allergy and Infectious Diseases (NIAID)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: UNK
Max Age: UNK

Referral Letter Required

No

Population Exclusion(s)

None

Special Instructions

Currently Not Provided

Keywords

Borrelia Burgdorferi;
lyme Disease;
Infection;
Therapy

Recruitment Keyword(s)

lyme Disease;
lyme

Condition(s)

lyme Disease

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Institute of Allergy and Infectious Diseases

This study is designed to establish a population of patients with lyme disease for evaluation, treatment and follow-up to learn more about the infection.

Patients with active lyme disease may be eligible for this study.

Participants will have a medical history and physical examination and diagnostic evaluations as appropriate to their individual condition. Laboratory tests may include routing blood and urine tests, X-rays, or other imaging studies, body fluid or tissue cultures, skin biopsy and tests for allergic or immune responses. Treatment will include only medications approved by the Food and Drug Administration, given according to accepted dose schedules and ways of taking the medicines. All diagnostic tests and treatments will be according to standard medical practice for the disease. No experimental procedures will be offered under this protocol.

Patients will be followed as needed for evaluation and treatment of their condition. In general, they will be asked to return at the end of therapy, then 3, 6 and 12 months later, and then every 6 to 12 months. More frequent visits may be required or less frequent visits may be allowed, depending on the individual s condition.

Participants may be asked to undergo the following additional procedures for research purposes:

- Extra blood draws to study lyme disease and other inflammatory conditions. Blood will be drawn from arm veins. The total amount drawn during any 6-week period will not exceed 450 cc (30 tablespoons) for adults and 7 cc (1/2 tablespoon) per kilogram (2.2 pounds) of body weight for children under 18 years of age.

- Leukapheresis to collect large numbers of white blood cells. Whole blood is collected through a needle in an arm vein, similar to donating blood. The blood circulates through a machine that separates it into its components, and the white cells are removed. The rest of the blood is returned to the body through the same needle. Only adults 18 years of age and older will be asked to undergo leukapheresis.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

Clinical diagnosis of active lyme disease at the time of the initial NIH evaluation based on the CDC case definition.

Subjects must maintain a private physician for non-protocol related medical complaints and for emergency medical treatment required for these or other of their disorders.

EXCLUSION CRITERIA:

Post treatment lyme disease syndrome.

Unacceptable poor compliance, which, in the opinion of the investigator, would interfere with one's ability to study or provide quality medical care for the patient.

ELIGIBILITY CRITERIA TO UNDERGO APHERESIS:

Age 18 years or above.

Weight greater than 110 pounds.

No known heart, lung, kidney disease, or bleeding disorders.

Negative HIV, HCV and HBsAg serologies.

Female subjects should not be pregnant or nursing.

Patients will have a CBC performed up to 2 weeks before the procedure. In order to be able to undergo the procedure, patient must fulfill all of the below:

Hemoglobin greater than 11 g/dL for males and greater than 10 g/dL for females.

Platelets greater than 150 k/mm(3).

WBC greater than 3.5 x 10(3) uL.

MCV above 80.

Women who are able to conceive children must have a negative pregnancy test within 2 weeks before the procedure.


--Back to Top--

Citations:

Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia

The clinical spectrum of early lyme borreliosis in patients with culture-confirmed erythema migrans

The early clinical manifestations of lyme disease

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Adriana R. Marques, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
BG 10 RM 12C118
10 CENTER DR
BETHESDA MD 20814
(301) 435-7244
amarques@niaid.nih.gov

Adriana R. Marques, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
BG 10 RM 12C118
10 CENTER DR
BETHESDA MD 20814
(301) 435-7244
amarques@niaid.nih.gov

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

prpl@mail.cc.nih.gov

Clinical Trials Number:

NCT00028080

--Back to Top--

QUESTIONS?

Contact the Patient Recruitment and Public Liaison Office for:

  • Details on how to participate in a study
  • Details on how to refer a patient to a study

NIH Clinical Studies Information Request


Contact the Office of Communications for:

  • General information about the NIH Clinical Center

www.cc.nih.gov/contact.shtml


Contact the Department Clinical Research Informatics, (DCRI) for:

  • Technical questions about Adobe Acrobat and the PDF format
  • Technical questions about this web server

webmaster@cc.nih.gov